Search

Your search keyword '"Mozas, Pablo"' showing total 191 results
Start Over Author "Mozas, Pablo"
191 results on '"Mozas, Pablo"'

3. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol

Author

Bataller, Alex, Garrido, Ana, Guijarro, Francesca, Oñate, Guadalupe, Diaz-Beyá, Marina, Arnan, Montserrat, Tormo, Mar, Vives, Susana, de Llano, María Paz Queipo, Coll, Rosa, Gallardo, David, Vall-Llovera, Ferran, Escoda, Lourdes, Garcia-Guiñon, Antonio, Salamero, Olga, Sampol, Antònia, Merchan, Brayan M., Bargay, Joan, Castaño-Díez, Sandra, Esteban, Daniel, Oliver-Caldés, Aina, Rivero, Andrea, Mozas, Pablo, López-Guerra, Mònica, Pratcorona, Marta, Zamora, Lurdes, Costa, Dolors, Rozman, Maria, Nomdedéu, Josep F., Colomer, Dolors, Brunet, Salut, Sierra, Jorge, and Esteve, Jordi

Published
2022
Full Text
View/download PDF

4. Risk scores predicting disease progression in early‐stage CLL: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy.

Author

Arguello‐Tomas, Miguel, Mozas, Pablo, Albiol, Nil, López‐Esteban, Miguel, Sierra, Jorge, Nomdedéu, Josep, Martinez‐Laperche, Carolina, Moga, Esther, Piñeyroa, Juan A., Delgado, Julio, Osorio, Santiago, and Moreno, Carol

Abstract

Background Methods Results Conclusion Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However, some patients require intervention shortly after diagnosis. In the past decade, several risk scores (RS) have been developed to predict disease progression, yet some patients are misclassified. On the other hand, IGHV subset 2 (IGHV2) predicts poor outcomes.A retrospective and multicentric study was conducted to compare the accuracy of five different RS (IPS‐E, CR0, AIPS‐E, CLL‐IPI, and Barcelona‐Brno) to predict disease progression in 781 stage A previously untreated patients with CLL. As an exploratory analysis, it was further investigated whether the inclusion of the IGHV2 as a poor prognostic parameter improved the accuracy of RS.All the scores identified a similar group of patients with CLL in early stage with low‐, intermediate‐, and high‐risk progression. Discrimination was high and similar in all RS (c‐index = 0.74–0.79, area under the curve = 0.7–0.75), as well as calibration (p = .98) and parsimony, although CLL‐IPI showed the best results (Akaike information criterion = 441). A total of 34.4% of patients were categorized within the same RS and concordance was at least moderate between RS.Moreover, the results suggest that IGHV2 may improve the accuracy of RS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

Author

Syrykh, Charlotte, primary, Pons-Brun, Berta, additional, Russiñol, Núria, additional, Playa-Albinyana, Heribert, additional, Baumann, Tycho, additional, Duran-Ferrer, Martí, additional, Kulis, Marta, additional, Carbó-Meix, Anna, additional, Mozas, Pablo, additional, Alcoceba, Miguel, additional, González, Marcos, additional, Navarro-Bailón, Almudena, additional, Colado, Enrique, additional, Payer, Ángel R., additional, Aymerich, Marta, additional, Terol, María J., additional, Lu, Junyan, additional, Knisbacher, Binyamin A., additional, Hahn, Cynthia K., additional, Ruiz-Gaspà, Sílvia, additional, Enjuanes, Anna, additional, Wu, Catherine J., additional, Getz, Gad, additional, Zenz, Thorsten, additional, López-Guillermo, Armando, additional, Martín-Subero, José I., additional, Colomer, Dolors, additional, Delgado, Julio, additional, Campo, Elías, additional, and Nadeu, Ferran, additional

Published
2023
Full Text
View/download PDF

9. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma

Author

Mozas, Pablo, primary, Casanueva‐Eliceiry, Sebastian, additional, Rivero, Andrea, additional, Serna, Ángel, additional, Simó, Marc, additional, Rodríguez, Sonia, additional, Rivas‐Delgado, Alfredo, additional, Nadeu, Ferran, additional, Correa, Juan Gonzalo, additional, Piñeyroa, Juan Antonio, additional, Pérez‐Valencia, Amanda Isabel, additional, Guinetti‐Ortiz, Katia, additional, Gómez‐Hernando, Marta, additional, Giné, Eva, additional, Delgado, Julio, additional, Villamor, Neus, additional, Campo, Elías, additional, Magnano, Laura, additional, Abrisqueta, Pau, additional, Setoain, Xavier, additional, and López‐Guillermo, Armando, additional

Published
2023
Full Text
View/download PDF

10. The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (ARI‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma

Author

Martínez‐Cibrián, Núria, primary, Ortiz‐Maldonado, Valentín, additional, Español‐Rego, Marta, additional, Blázquez, Andrea, additional, Cid, Joan, additional, Lozano, Miquel, additional, Magnano, Laura, additional, Giné, Eva, additional, Correa, Juan G., additional, Mozas, Pablo, additional, Rodríguez‐Lobato, Luis Gerardo, additional, Rivero, Andrea, additional, Montoro‐Lorite, Mercedes, additional, Ayora, Pilar, additional, Navarro, Sergio, additional, Alserawan, Leticia, additional, González‐Navarro, E. Azucena, additional, Castellà, Maria, additional, Sánchez‐Castañón, María, additional, Cabezón, Raquel, additional, Benítez‐Ribas, Daniel, additional, Setoaín, Xavier, additional, Rodríguez, Sonia, additional, Brillembourg, Helena, additional, Varea, Sara, additional, Olesti, Eulalia, additional, Guillén, Elena, additional, Sáez‐Peñataro, Joaquín, additional, de Larrea, Carlos Fernández, additional, López‐Guillermo, Armando, additional, Pascal, Mariona, additional, Urbano‐Ispizua, Álvaro, additional, Juan, Manel, additional, and Delgado, Julio, additional

Published
2023
Full Text
View/download PDF

11. The academic point‐of‐care anti‐CD19 chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (ARI‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell non‐Hodgkin lymphoma

Author

Martínez‐Cibrián, Núria, Ortiz‐Maldonado, Valentín, Español‐Rego, Marta, Blázquez, Andrea, Cid, Joan, Lozano, Miquel, Magnano, Laura, Giné, Eva, Correa, Juan G., Mozas, Pablo, Rodríguez‐Lobato, Luis Gerardo, Rivero, Andrea, Montoro‐Lorite, Mercedes, Ayora, Pilar, Navarro, Sergio, Alserawan, Leticia, González‐Navarro, E. Azucena, Castellà, Maria, Sánchez‐Castañón, María, and Cabezón, Raquel

Subjects
CHIMERIC antigen receptors, NON-Hodgkin's lymphoma, CYTOKINE release syndrome, T cells, HOCKEY
Abstract

Summary: Varnimcabtagene autoleucel (var‐cel) is an academic anti‐CD19 chimeric antigen receptor (CAR) product used for the treatment of non‐Hodgkin lymphoma (NHL) in the CART19‐BE‐01 trial. Here we report updated outcomes of patients with NHL treated with var‐cel. B‐cell recovery was compared with patients with acute lymphoblastic leukaemia (ALL). Forty‐five patients with NHL were treated. Cytokine release syndrome (any grade) occurred in 84% of patients (4% grade ≥3) and neurotoxicity in 7% (2% grade ≥3). The objective response rate was 73% at Day +100, and the 3‐year duration of response was 56%. The 3‐year progression‐free and overall survival were 40% and 52% respectively. High lactate dehydrogenase was the only covariate with an impact on progression‐free survival. The 3‐year incidence of B‐cell recovery was lower in patients with NHL compared to ALL (25% vs. 60%). In conclusion, in patients with NHL, the toxicity of var‐cel was manageable, while B‐cell recovery was significantly prolonged compared to ALL. This trial was registered as NCT03144583. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. A low total metabolic tumor volume independently predicts for a longer time to first treatment in initially observed, low tumor burden follicular lymphoma.

Author

Mozas, Pablo, Casanueva‐Eliceiry, Sebastian, Rivero, Andrea, Serna, Ángel, Simó, Marc, Rodríguez, Sonia, Rivas‐Delgado, Alfredo, Nadeu, Ferran, Correa, Juan Gonzalo, Piñeyroa, Juan Antonio, Pérez‐Valencia, Amanda Isabel, Guinetti‐Ortiz, Katia, Gómez‐Hernando, Marta, Giné, Eva, Delgado, Julio, Villamor, Neus, Campo, Elías, Magnano, Laura, Abrisqueta, Pau, and Setoain, Xavier

Subjects
FOLLICULAR lymphoma, POSITRON emission tomography computed tomography, POSITRON emission tomography, WATCHFUL waiting
Abstract

Watchful waiting is an acceptable management strategy for advanced‐stage, low tumor burden (LTB) patients with follicular lymphoma (FL). However, the prediction of how long this treatment‐free observation period will last remains imperfect. We explored whether total metabolic tumor volume (TMTV) and other positron emission tomography parameters were predictive of time to first treatment (TTFT). We analyzed 97 grade 1–3A advanced‐stage LTB FL patients and found that a high TMTV was associated with other tumor burden features at diagnosis. Patients with a TMTV above our established cutoff of 50 mL had a significantly shorter median duration of observation (2.6 vs. 8.8 years; p = 0.001). At 5 years, 77% of patients with a high TMTV and 46% of patients with a low TMTV required treatment. In the multivariable analysis, a high TMTV was the only independent factor predicting TTFT (hazard ratio = 2.09; p = 0.017). Overall, TMTV is a strong predictor of the duration of observation in LTB FL patients. Upon validation of our cutoff in external series and standardization of the methodology, the TMTV could become an additional factor to consider deferring or initiating treatment in otherwise LTB patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia

Author

López-Oreja, Irene, primary, López-Guerra, Mónica, additional, Correa, Juan, additional, Mozas, Pablo, additional, Muntañola, Ana, additional, Muñoz, Luz, additional, Salgado, Ana-Camino, additional, Ruiz-Gaspà, Sílvia, additional, Costa, Dolors, additional, Beà, Sílvia, additional, Jares, Pedro, additional, Campo, Elías, additional, Colomer, Dolors, additional, and Nadeu, Ferran, additional

Published
2023
Full Text
View/download PDF

14. P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA

Author

Martinez-Cibrian, Nuria, primary, Ortiz-Maldonado, Valentín, additional, Español-Rego, Marta, additional, Benitez-Ribas, Daniel, additional, Cid, Joan, additional, Lozano, Miquel, additional, Navarro, Sergio, additional, Magnano, Laura, additional, Gine, Eva, additional, Saldarriaga, Juan Gonzalo Correa, additional, Mozas, Pablo, additional, Lobato, Luis Gerardo Rodríguez, additional, Brillembourg, Helena, additional, Montoro, Mercedes, additional, Ayora, Pilar, additional, Alserawan, Leticia, additional, Martínez Roca, Alexandra, additional, Lopez-Guillermo, Armando, additional, Urbano Ispizua, Avaro, additional, Juan, Manel, additional, Pascal, Mariona, additional, and Delgado, Julio, additional

Published
2023
Full Text
View/download PDF

17. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors.

Author

Mozas, Pablo, López, Cristina, Grau, Marta, Nadeu, Ferran, Clot, Guillem, Valle, Sara, Kulis, Marta, Navarro, Alba, Ramis‐Zaldivar, Joan Enric, González‐Farré, Blanca, Rivas‐Delgado, Alfredo, Rivero, Andrea, Frigola, Gerard, Balagué, Olga, Giné, Eva, Delgado, Julio, Villamor, Neus, Matutes, Estella, Magnano, Laura, and García‐Sanz, Ramón

Subjects
FOLLICULAR lymphoma, NUCLEOTIDE sequencing, LYMPHOID tissue, PROTEIN models, GENOMICS
Abstract

While some follicular lymphoma (FL) patients do not require treatment or experience prolonged responses, others relapse early, and little is known about genetic alterations specific to patients with a particular clinical behavior. We selected 56 grade 1–3A FL patients according to their need of treatment or timing of relapse: never treated (n = 7), non‐relapsed (19), late relapse (14), early relapse or POD24 (11), and primary refractory (5). We analyzed 56 diagnostic and 12 paired relapse lymphoid tissue biopsies and performed copy number alteration (CNA) analysis and next generation sequencing (NGS). We identified six focal driver losses (1p36.32, 6p21.32, 6q14.1, 6q23.3, 9p21.3, 10q23.33) and 1p36.33 copy‐neutral loss of heterozygosity (CN‐LOH). By integrating CNA and NGS results, the most frequently altered genes/regions were KMT2D (79%), CREBBP (67%), TNFRSF14 (46%) and BCL2 (40%). Although we found that mutations in PIM1, FOXO1 and TMEM30A were associated with an adverse clinical behavior, definitive conclusions cannot be drawn, due to the small sample size. We identified common precursor cells harboring early oncogenic alterations of the KMT2D, CREBBP, TNFRSF14 and EP300 genes and 16p13.3‐p13.2 CN‐LOH. Finally, we established the functional consequences of mutations by means of protein modeling (CD79B, PLCG2, PIM1, MCL1 and IRF8). These data expand the knowledge on the genomics behind the heterogeneous FL population and, upon replication in larger cohorts, could contribute to risk stratification and the development of targeted therapies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Supplementary tables from Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study

Author

Rivas-Delgado, Alfredo, primary, Nadeu, Ferran, primary, Enjuanes, Anna, primary, Casanueva-Eliceiry, Sebastián, primary, Mozas, Pablo, primary, Magnano, Laura, primary, Castrejón de Anta, Natalia, primary, Rovira, Jordina, primary, Dlouhy, Ivan, primary, Martín, Silvia, primary, Osuna, Miguel, primary, Rodríguez, Sonia, primary, Simó, Marc, primary, Pinyol, Magda, primary, Baumann, Tycho, primary, Beà, Silvia, primary, Balagué, Olga, primary, Delgado, Julio, primary, Villamor, Neus, primary, Setoain, Xavier, primary, Campo, Elías, primary, Giné, Eva, primary, and López-Guillermo, Armando, primary

Published
2023
Full Text
View/download PDF

19. MALAT1Expression is Associated with Aggressive Behavior in Indolent B-Cell Neoplasms

Author

María Fernández-Garnacho, Elena, primary, Nadeu, Ferran, additional, Martín, Silvia, additional, Mozas, Pablo, additional, Rivero, Andrea, additional, Delgado, Julio, additional, Giné, Eva, additional, López-Guillermo, Armando, additional, Duran-Ferrer, Martí, additional, Salaverria, Itziar, additional, López, Cristina, additional, Beà, Sílvia, additional, Demajo, Santiago, additional, Jares, Pedro, additional, Puente, Xose S, additional, Martín-Subero, José Ignacio, additional, Campo, Elias, additional, and Hernández, Lluís, additional

Published
2023
Full Text
View/download PDF

20. Lesions mimicking colonic polyposis

Author

Hernández-Évole, Helena, primary, Soy, Guillem, additional, Mozas, Pablo Javier, additional, Araujo, Isis K., additional, and Fernández-Esparrach, Glòria, additional

Published
2023
Full Text
View/download PDF

21. Immunocompetent 3D Follicular Lymphoma Model: A Preclinical Tool to Design Tailored Immunotherapies

Author

Dobaño-López, Cèlia, primary, Valero, Juan G, additional, Araujo-Ayala, Ferran, additional, Nadeu, Ferran, additional, Gava, Fabien, additional, Faria, Carla, additional, Norlund, Marine, additional, Morin, Renaud, additional, Bernes-Lasserre, Pascale, additional, Serrat, Neus, additional, Playa-Albinyana, Heribert, additional, Rivero, Andrea, additional, Mozas, Pablo, additional, Campo, Elías, additional, Lagarde, Jean-Michel, additional, López-Guillermo, Armando, additional, Colomer, Dolors, additional, Bezombes, Christine, additional, and Pérez-Galán, Patricia, additional

Published
2022
Full Text
View/download PDF

22. Flow cytometry to detect bone marrow involvement by follicular lymphoma

Author

Aren, Mercè, primary, Marce, Silvia, additional, Jurado, Rebeca, additional, Tapia, Gustavo, additional, Puigdefabregues, Lluís, additional, Raya, Minerva, additional, Cortes, Montserrat, additional, Garcia‐Caro, Montse, additional, Junca, Jordi, additional, Mozas, Pablo, additional, Viñets, Esther, additional, Cabezon, Marta, additional, Plensa, Esther, additional, Miljkovic, Milos, additional, Sancho, Juan‐Manuel, additional, Navarro, José‐Tomas, additional, Zamora, Lurdes, additional, and Sorigue, Marc, additional

Published
2022
Full Text
View/download PDF

23. Cutaneous T-cell lymphoma care across Europe: insights from the HORIZON programme.

Author

Roccuzzo, Gabriele, Calvão, Joana, Dobos, Gabor, Morsia, Erika, Mozas, Pablo, Peterknecht, Elizabeth, Schrader, Anne M R, Zottarelli, Francesca, Bagot, Martine, Stadler, Rudolf, Vermeer, Maarten, Quaglino, Pietro, and Scarisbrick, Julia

Subjects
CUTANEOUS T-cell lymphoma, SEZARY syndrome, HIGH mobility group proteins, MEDICAL personnel
Abstract

The article discusses the challenges and complexities of diagnosing and treating cutaneous T-cell lymphoma (CTCL), a rare group of non-Hodgkin lymphomas that primarily affect the skin. The lack of standardized approaches and specialized training programs for skin lymphoma specialists in Europe has led to divergent approaches in patient care. The HORIZON program, which involved clinical and research rotations across five European centers, aimed to address this gap and foster a collaborative global network. The rotations provided valuable insights into diagnostics, therapeutics, and research methodologies, including the use of advanced techniques and technologies. Consistency was observed in adopting both traditional and newer treatments, aligning with the latest guidelines. The involvement of clinical nurse specialists, particularly in the UK, was noted as an opportunity for holistic and comprehensive patient-centered care. The program has laid the groundwork for a collaborative network and ongoing research projects. A second program is planned for 2025. The article was funded by Kyowa Kirin International PLC, and the authors declare no conflicts of interest. [Extracted from the article]

Published
2024
Full Text
View/download PDF

27. Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Oliver-Caldes, Aina, primary, Soler-Perromat, Juan Carlos, additional, Lozano, Ester, additional, Moreno, David, additional, Bataller, Alex, additional, Mozas, Pablo, additional, Garrote, Marta, additional, Setoain, Xavier, additional, Aróstegui, Juan Ignacio, additional, Yagüe, Jordi, additional, Tovar, Natalia, additional, Jiménez, Raquel, additional, Rodríguez-Lobato, Luis Gerardo, additional, Cibeira, M. Teresa, additional, Rosiñol, Laura, additional, Bladé, Joan, additional, Juan, Manel, additional, and Fernández de Larrea, Carlos, additional

Published
2022
Full Text
View/download PDF

29. Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma

Author

Rivas-Delgado, Alfredo, primary, Nadeu, Ferran, additional, Andrade-Campos, Marcio, additional, López, Cristina, additional, Enjuanes, Anna, additional, Mozas, Pablo, additional, Frigola, Gerard, additional, Colomo, Luis, additional, Sanchez-Gonzalez, Blanca, additional, Villamor, Neus, additional, Beà, Sílvia, additional, Campo, Elías, additional, Salar, Antonio, additional, Giné, Eva, additional, López-Guillermo, Armando, additional, and Bellosillo, Beatriz, additional

Published
2022
Full Text
View/download PDF

30. Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia

Author

Piñeyroa, Juan A., primary, Magnano, Laura, additional, Rivero, Andrea, additional, Rivas‐Delgado, Alfredo, additional, Nadeu, Ferran, additional, Correa, Juan Gonzalo, additional, Giné, Eva, additional, Villamor, Neus, additional, Filella, Xavier, additional, Colomer, Dolors, additional, López, Mònica, additional, López‐Oreja, Irene, additional, Costa, Dolors, additional, Aymerich, Marta, additional, Beà, Sílvia, additional, López‐Guillermo, Armando, additional, Campo, Elías, additional, Delgado, Julio, additional, and Mozas, Pablo, additional

Published
2022
Full Text
View/download PDF

31. Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders.

Author

Güell, Nadia, Mozas, Pablo, Jimenez-Rueda, Alba, Miljkovic, Milos, Juncà, Jordi, and Sorigue, Marc

Subjects
*CHRONIC lymphocytic leukemia diagnosis, *FLOW cytometry, *CHRONIC lymphocytic leukemia, *AUTOANTIBODIES, *B cells, *PREDICTIVE tests, *IMMUNOGLOBULINS, *IMMUNOLOGIC receptors, *CONCEPTUAL structures, *CANCER patients, *INTER-observer reliability, *DESCRIPTIVE statistics, *LYMPHOPROLIFERATIVE disorders, *SENSITIVITY & specificity (Statistics), *TUMOR markers, *DATA analysis software, *LOGISTIC regression analysis, *RECEIVER operating characteristic curves
Abstract

The diagnosis of leukemic B-cell lymphoproliferative disorders (B-LPDs) is made by integrating clinical, cytological, cytometric, cytogenetic, and molecular data. This leaves room for differences and inconsistencies between experts. In this study, we examine methodological and conceptual aspects of the flow cytometric classification of leukemic B-LPDs that could explain them. Among methodological aspects, we discuss (1) the different statistical tests used to select and evaluate markers, (2) how these markers are analyzed, (3) how scores are interpreted, (4) different degrees to which diagnostic information is used, and (5) and the impact of differences in study populations. Among conceptual aspects, we discuss (1) challenges to integrating different biological data points, (2) the under examination of the costs of misclassification (false positives and false negatives), and finally, (3) we delve into the impact of the lack of a true diagnostic gold standard and the indirect evidence suggesting poor reproducibility in the diagnosis of leukemic B-LPDs. We then outline current harmonization efforts and our personal approach. We conclude that numerous flow cytometry scores and diagnostic systems are now available; however, as long as the considerations discussed remain unaddressed, external reproducibility and interobserver agreement will not be achieved, and the field will not be able to move forward if a true gold standard is not found. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Early progression in follicular lymphoma in the absence of histological transformation or high‐risk Follicular Lymphoma International Prognostic Index still has a favourable outcome.

Author

Muntañola, Ana, Mozas, Pablo, Mercadal, Santiago, Huguet, Maria, Bobillo, Sabela, Bastos‐Oreiro, Mariana, Jiménez‐Ubieto, Ana, Rovira, Jordina, Rivero, Andrea, Tolosa, Carles, Luizaga, Luis, de Villambrosia, Sonia González, Novelli, Silvana, Caballero, Dolores, Salar, Antonio, Alonso‐Álvarez, Sara, Magnano, Laura, Gutiérrez, Norma C., Sancho, Juan‐Manuel, and López‐Guillermo, Armando

Subjects
*FOLLICULAR lymphoma, *LACTATE dehydrogenase, *SALVAGE therapy, *PROGNOSIS, *DISEASE relapse
Abstract

Summary: Although follicular lymphoma (FL) patients relapsing within 24 months after first‐line treatment (POD24) have a poor prognosis, some cases show notable survival after first relapse (SF1R). We aimed to characterize the POD24 FL population and to identify the main prognostic factors at progression. We selected 162 POD24 patients (80F; median age at first relapse 59 years) from a cohort of 1067 grades 1‐3a FL‐treated patients. The remaining 905 patients treated with first‐line immunochemotherapy and diagnosed during the same period were used to compare outcomes in terms of survival. After a median follow‐up of 11.0 years, 96 patients died (10y‐SF1R of 40%). Age over 60 years (p < 0.001), high lactate dehydrogenase (LDH) (p < 0.001), haemoglobin (Hb) less than 120 g/L (p < 0.001), advanced stage (p < 0.001), high‐risk Follicular Lymphoma International Prognostic Index (FLIPI) (p < 0.001), histological transformation (HT) (p < 0.001) and reaching less than complete response (CR) after salvage therapy (p < 0.001), predicted poor SF1R at relapse. In multivariate analysis only high‐risk FLIPI and HT maintained prognostic significance for SF1R. POD24 patients not transformed and with low/intermediate FLIPI at relapse behaved better than the remaining cases. POD24 patients showed an excess mortality of 38% compared to the general population. Although outcome of POD24 FL patients is poor, a considerable group of them (low/intermediate FLIPI and not transformed at first relapse) behave better. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models

Author

Mosquera Orgueira, Adrián, primary, Cid López, Miguel, additional, Peleteiro Raíndo, Andrés, additional, Abuín Blanco, Aitor, additional, Díaz Arias, Jose Ángel, additional, González Pérez, Marta Sonia, additional, Antelo Rodríguez, Beatriz, additional, Bao Pérez, Laura, additional, Ferreiro Ferro, Roi, additional, Aliste Santos, Carlos, additional, Pérez Encinas, Manuel Mateo, additional, Fraga Rodríguez, Máximo Francisco, additional, Cerchione, Claudio, additional, Mozas, Pablo, additional, and Bello López, José Luis, additional

Published
2022
Full Text
View/download PDF

34. KMT2A-CBLrearrangements in acute leukemias: clinical characteristics and genetic breakpoints

Author

Bataller, Alex, primary, Guijarro, Francesca, additional, Caye-Eude, Aurélie, additional, Strullu, Marion, additional, Sterin, Arthur, additional, Molina, Oscar, additional, Chevallier, Patrice, additional, Zaliova, Marketa, additional, Zuna, Jan, additional, Mozas, Pablo, additional, Magnano, Laura, additional, Grardel, Nathalie, additional, Cornillet-Lefebvre, Pascale, additional, Fu, Jen-Fen, additional, Shih, Lee-Yung, additional, Boneva, Temenuzhka, additional, Nacheva, Elisabeth, additional, Beà, Silvia, additional, López-Guerra, Mònica, additional, Bueno, Clara, additional, Menéndez, Pablo, additional, Esteve, Jordi, additional, Larghero, Patrizia, additional, Meyer, Claus, additional, and Marschalek, Rolf, additional

Published
2021
Full Text
View/download PDF

35. First external validation of the FLIPI‐L score in a single‐centre series of patients with follicular lymphoma

Author

Mozas, Pablo, primary, Rivero, Andrea, additional, Rivas‐Delgado, Alfredo, additional, Correa, Juan Gonzalo, additional, Condom, Maria, additional, Nadeu, Ferran, additional, Giné, Eva, additional, Delgado, Julio, additional, Villamor, Neus, additional, Campo, Elías, additional, Magnano, Laura, additional, and López‐Guillermo, Armando, additional

Published
2021
Full Text
View/download PDF

36. The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma

Author

Mozas, Pablo, primary, Rivero, Andrea, additional, Rivas-Delgado, Alfredo, additional, Nadeu, Ferran, additional, Giné, Eva, additional, Delgado, Julio, additional, Villamor, Neus, additional, Campo, Elías, additional, Pérez-Galán, Patricia, additional, Magnano, Laura, additional, and López-Guillermo, Armando, additional

Published
2021
Full Text
View/download PDF

38. Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma

Author

Dlouhy, Ivan, primary, Karube, Kennosuke, additional, Enjuanes, Anna, additional, Salaverria, Itziar, additional, Nadeu, Ferran, additional, Ramis‐Zaldivar, Juan Enric, additional, Valero, Juan G., additional, Rivas‐Delgado, Alfredo, additional, Magnano, Laura, additional, Martin‐García, David, additional, Pérez‐Galán, Patricia, additional, Clot, Guillem, additional, Rovira, Jordina, additional, Jares, Pedro, additional, Balagué, Olga, additional, Giné, Eva, additional, Mozas, Pablo, additional, Briones, Javier, additional, Sancho, Juan‐Manuel, additional, Salar, Antonio, additional, Mercadal, Santiago, additional, Alcoceba, Miguel, additional, Valera, Alexandra, additional, Campo, Elías, additional, and López‐Guillermo, Armando, additional

Published
2021
Full Text
View/download PDF

40. Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation

Author

Mozas, Pablo, primary, Rivero, Andrea, additional, Rivas‐Delgado, Alfredo, additional, Correa, Juan Gonzalo, additional, Condom, Maria, additional, Nadeu, Ferran, additional, Giné, Eva, additional, Delgado, Julio, additional, Villamor, Neus, additional, Campo, Elías, additional, Magnano, Laura, additional, and López‐Guillermo, Armando, additional

Published
2021
Full Text
View/download PDF

41. Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution

Author

Rivero, Andrea, primary, Mozas, Pablo, additional, Jiménez, Laura, additional, López-Guerra, Mónica, additional, Colomer, Dolors, additional, Bataller, Alex, additional, Correa, Juan, additional, Rivas-Delgado, Alfredo, additional, Bastidas, Gabriela, additional, Baumann, Tycho, additional, Martínez-Trillos, Alejandra, additional, Delgado, Julio, additional, Giné, Eva, additional, Campo, Elías, additional, López-Guillermo, Armando, additional, Villamor, Neus, additional, Magnano, Laura, additional, and Matutes, Estella, additional

Published
2021
Full Text
View/download PDF

43. The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma.

Author

Mozas, Pablo, Rivero, Andrea, Rivas-Delgado, Alfredo, Nadeu, Ferran, Giné, Eva, Delgado, Julio, Villamor, Neus, Campo, Elías, Pérez-Galán, Patricia, Magnano, Laura, and López-Guillermo, Armando

Subjects
*OLDER patients, *FOLLICULAR lymphoma, *OVERALL survival, *LYMPHOCYTE count, *SERUM albumin
Abstract

The Prognostic Nutritional Index (PNI), a parameter combining serum albumin concentration and absolute lymphocyte count, is considered a measure of the nutritional and inflammatory status and the host's anti-tumor response. We analyzed the clinical characteristics and outcomes according to the PNI of 351 grades 1–3 A FL patients. Forty-one patients (12%) had a PNI ≤45, who were older and showed adverse baseline features. A low PNI was associated with a shorter PFS (only for patients >60 years), and OS (for all patients, 10-year OS, 52% versus 74%, p = 0.0001). The prognostic impact of the PNI on OS was confirmed in a multivariate model for patients >60 years (HR = 3, p = 0.006). In conclusion, the PNI is a readily accessible piece of information that can identify a small subset of FL patients with shorter survival, and it could be an aid to improve the nutritional status of patients prior to treatment initiation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. First external validation of the FLIPI‐L score in a single‐center series of patients with follicular lymphoma.

Author

Mozas, Pablo, Rivero, Andrea, Rivas‐Delgado, Alfredo, Correa, Juan Gonzalo, Condom, Maria, Nadeu, Ferran, Giné, Eva, Delgado, Julio, Villamor, Neus, Campo, Elías, Magnano, Laura, and López‐Guillermo, Armando

Subjects
FOLLICULAR lymphoma, PROGRESSION-free survival, OVERALL survival, LYMPHOPENIA
Abstract

The FLIPI‐L has recently been proposed as a novel prognostic index in follicular lymphoma (FL), combining FLIPI and the presence of lymphopenia. In our single‐center validation in 381 FL patients, lymphopenia was less frequent than in the original publication and thus the distribution of risk categories was different. Although it was not able to properly predict time to first treatment, FLIPI‐L performed slightly better than FLIPI alone in the prediction of response, early relapse, progression‐free and overall survival, and histological transformation. This new tool or others encompassing parameters from the microenvironment might improve upon the prognostic ability of classical scores. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study

Author

Rivas-Delgado, Alfredo, primary, Nadeu, Ferran, additional, Enjuanes, Anna, additional, Casanueva-Eliceiry, Sebastián, additional, Mozas, Pablo, additional, Magnano, Laura, additional, Castrejón de Anta, Natalia, additional, Rovira, Jordina, additional, Dlouhy, Ivan, additional, Martín, Silvia, additional, Osuna, Miguel, additional, Rodríguez, Sonia, additional, Simó, Marc, additional, Pinyol, Magda, additional, Baumann, Tycho, additional, Beà, Silvia, additional, Balagué, Olga, additional, Delgado, Julio, additional, Villamor, Neus, additional, Setoain, Xavier, additional, Campo, Elías, additional, Giné, Eva, additional, and López-Guillermo, Armando, additional

Published
2021
Full Text
View/download PDF

46. The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients

Author

Mozas, Pablo, primary, Sorigué, Marc, additional, Rivas‐Delgado, Alfredo, additional, Rivero, Andrea, additional, Correa, Juan G., additional, Castillo, Carlos, additional, Nadeu, Ferran, additional, Bataller, Alex, additional, Giné, Eva, additional, Baumann, Tycho, additional, Delgado, Julio, additional, Villamor, Neus, additional, Campo, Elias, additional, Magnano, Laura, additional, Sancho, Juan‐Manuel, additional, and López‐Guillermo, Armando, additional

Published
2020
Full Text
View/download PDF

47. Baseline correlations and prognostic impact of serum monoclonal proteins in follicular lymphoma

Author

Mozas, Pablo, primary, Rivero, Andrea, additional, Rivas‐Delgado, Alfredo, additional, Fabregat, Aleix, additional, Piñeyroa, Juan A., additional, Correa, Juan G., additional, Nadeu, Ferran, additional, Oliver, Aina, additional, Bataller, Alex, additional, Giné, Eva, additional, Delgado, Julio, additional, Villamor, Neus, additional, Cibeira, Maria T., additional, Fernández de Larrea, Carlos, additional, Rosiñol, Laura, additional, Campo, Elías, additional, Aróstegui, Juan I., additional, Bladé, Joan, additional, Magnano, Laura, additional, and López‐Guillermo, Armando, additional

Published
2020
Full Text
View/download PDF

48. Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact

Author

Mozas, Pablo, primary, Pineyroa, Juan A., additional, Nadeu, Ferran, additional, Magnano, Laura, additional, Rivero, Andrea, additional, Rivas-Delgado, Alfredo, additional, Bataller, Alex, additional, Fabregat, Aleix, additional, Gine, Eva, additional, Baumann, Tycho, additional, Villamor, Neus, additional, Arostegui, Juan Ignacio, additional, Aymerich, Marta, additional, Lopez-Guillermo, Armando, additional, Campo, Elias, additional, and Delgado, Julio, additional

Published
2020
Full Text
View/download PDF

49. Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior

Author

Mozas, Pablo, primary, López, Cristina, additional, Grau, Marta, additional, Valle, Sara, additional, Castellano, Giancarlo, additional, Navarro, Alba, additional, Nadeu, Ferran, additional, González-Farré, Blanca, additional, Rivas-Delgado, Alfredo, additional, Rivero, Andrea, additional, Correa, Juan Gonzalo, additional, Castillo, Carlos, additional, Olga, Balagué, additional, Giné, Eva, additional, Delgado, Julio, additional, Villamor, Neus, additional, Pinyol, Magda, additional, Pérez-Galán, Patricia, additional, Magnano, Laura, additional, Campo, Elías, additional, Enjuanes, Anna, additional, Beà, Sílvia, additional, and Armando, López-Guillermo, additional

Published
2020
Full Text
View/download PDF

50. Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma.

Author

Dlouhy, Ivan, Karube, Kennosuke, Enjuanes, Anna, Salaverria, Itziar, Nadeu, Ferran, Ramis‐Zaldivar, Juan Enric, Valero, Juan G., Rivas‐Delgado, Alfredo, Magnano, Laura, Martin‐García, David, Pérez‐Galán, Patricia, Clot, Guillem, Rovira, Jordina, Jares, Pedro, Balagué, Olga, Giné, Eva, Mozas, Pablo, Briones, Javier, Sancho, Juan‐Manuel, and Salar, Antonio

Subjects
ANTINEOPLASTIC combined chemotherapy protocols, CELL cycle regulation, EXTRACELLULAR matrix, GENE expression profiling, DIFFUSE large B-cell lymphomas, TUMOR microenvironment
Abstract

Summary: Relapsed or refractory diffuse large B‐cell lymphoma (DLBCL) cases have a poor outcome. Here we analysed clinico‐biological features in 373 DLBCL patients homogeneously treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP), in order to identify variables associated with early failure to treatment (EF), defined as primary refractoriness or relapse within 12 months from diagnosis. In addition to clinical features, mutational status of 106 genes was studied by targeted next‐generation sequencing in 111 cases, copy number alterations in 87, and gene expression profile (GEP) in 39. Ninety‐seven cases (26%) were identified as EF and showed significantly shorter overall survival (OS). Patients with B symptoms, advanced stage, high levels of serum lactate dehydrogenase (LDH) or β2‐microglobulin, low lymphocyte/monocyte ratio and higher Revised International Prognostic Index (R‐IPI) scores, as well as those with BCL2 rearrangements more frequently showed EF, with R‐IPI being the most important in logistic regression. Mutations in NOTCH2, gains in 5p15·33 (TERT), 12q13 (CDK2), 12q14·1 (CDK4) and 12q15 (MDM2) showed predictive importance for EF independently from R‐IPI. GEP studies showed that EF cases were significantly enriched in sets related to cell cycle regulation and inflammatory response, while cases in response showed over‐representation of gene sets related to extra‐cellular matrix and tumour microenvironment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results